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ABSTRACT
Objectives: This study was designed to simulate standard and optimized dosing regimens for 
intravenous antibiotics against contemporary populations of Escherichia coli, Klebsiella pneumoniae, 
Acinetobacter baumannii, and Pseudomonas aeruginosa using MIC distribution data to determine 
which of the tested carbapenem regimens provided the greatest opportunity for obtaining 
maximal pharmacodynamic (PD) activity. Methods: The isolates studied were obtained from the 
COMPACT-COLOMBIA surveillance program conducted between February and November 2009. 
Antimicrobial susceptibility testing was conducted by broth microdilution method according 
to the CLSI guidelines. Doripenem, imipenem-cilastatin, and meropenem, were the modeled 
antibiotics. A 5,000 patient Monte Carlo simulation was performed for each regimen and PD targets 
were defined as free drug concentrations above the MIC for at least 40% of the dosing interval. 
Results: All carbapenem regimens obtained optimal exposures against E. coli, unlike the other 
Enterobacteriaceae tested. Against P. aeruginosa, only a prolonged infusion of doripenem exceeded 
the 90% cumulative fraction of response (CFR) threshold. Worrisomely, no regimens for any of the 
drugs tested obtained optimal CFR against A. baumannii. For P. aeruginosa intensive care unit (ICU) 
isolates, CFR was approximately 20% lower for isolates collected in the respiratory tract compared 
with bloodstream or intra-abdominal for imipenem and meropenem. Noteworthy, all doripenem 
and meropenem regimens achieved greater than 90% CFR against bloodstream and respiratory 
isolates of K. pneumoniae. Conclusions: Our data suggests that higher dosing and prolonged infusion 
of doripenem or meropenem may be suitable for empirically treating ICU P. aeruginosa, while none of 
the carbapenems achieved optimal cumulative fraction of response against A. baumannii. Standard 
dosing regimens of all the carbapenems tested achieved optimal CFR against E. coli isolates, but 
higher carbapenem dosages might be required for empiric treatment of K. pneumoniae, particularly 
from an intra-abdominal source. Non-standard dosage regimens studied in this modeling should be 
proven effective in prospective clinical trials. 
Keywords: drug resistance, bacterial; Gram-negative bacteria; Monte Carlo Method; Colombia; 
pharmacology.
INTRODUCTION
There is tremendous variability in antimicrobial 
resistance not only amongst pathogens 
causing various clinical infections in different 
geographic regions. Therefore, continuous 
surveillance of the extent and trends of 
antimicrobial resistance is necessary. Infections 
produced by Gram-negative bacilli (i.e. 
Escherichia coli and Klebsiella pneumoniae) and 
non-fermenters (i.e. Acinetobacter baumannii 
and Pseudomonas aeruginosa) continue to be 
of key importance in the Intensive Care Unit 
(ICU), as they have been considered important 
determinants of hospital mortality, prolonged 
hospitalization and increased health-care costs 
as compared to infections caused by non-
resistant bacteria.
Alarmingly, a limited number of antimicro-
bials retain some potency against these 
increasing resistant pathogens and novel 
therapies currently in the developmental pipe-
line appears to be years away from the wide 
scale clinical use. Hence, it is crucial to employ 
these currently available agents responsibly 
and effectively to extend their usefulness for 
the coming years.
The potency/effectiveness of antimicrobial 
therapy may be considered in terms of their in 
vitro and in vivo activity against the microor-
ganism of interest. To maximize the probability 
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of successful outcomes against theses difficult pathogens, sev-
eral strategies have been utilized including combination therapy 
and/or pharmacodynamic (PD) optimization. The latter ap-
proach has become increasingly utilized in the clinical setting as 
a means of achieving maximal bacteria kill and reducing the risk 
of the emergence of resistant bacteria. Therefore, once the deci-
sion regarding the choice of antimicrobial has been made, it is 
necessary to ensure that the dose, frequency of administration, 
and duration over which the agent is infused are optimized.
The aim of the PASSPORT (Probability of target 
attainment of Antibacterial agents Studied for Suscepti-
bility and Pharmacodynamic Optimization in Regional 
Trials) program is designed to simulate standard and opti-
mized dosing regimens for common intravenous antibiotics 
against contemporary populations of E. coli, K. pneumoniae, 
A. baumannii, and P. aeruginosa using MIC distribu-
tion data from isolates collected across the globe. In 
this report, isolates collected during the COMPACT 
(Comparative Activity of Carbape em Testing E-test 
studying)-COLOMBIAN surveillance study were analyzed 
to determine which of the tested carbapenem regimens 
provided the greatest opportunity for pharmacodynamic 
optimization. The COMPACT-COLOMBIAN surveil-
lance study was carried out by The International Center 
for Medical Research and Training (CIDEIM) with the 
objective of increasing the knowledge on the susceptibil-
ity to antibiotics of Gram-negative bacteria causing seri-
ous infections in hospitalized patients.
MATERIALS AND METHODS
Antimicrobials
Antimicrobials were included in the pharmaco-
dynamic model if they had comparative minimum 
inhibitory concentration (MIC) data available from the 
COMPACT-COLOMBIAN study. The following intrave-
nous carbapenem regimens were modeled:
• doripenem 500 mg, 1,000 mg, and 2,000 mg every  
 8 hours (1-hour and 4-hour infusions)
• imipenem-cilastatin 500 mg every 6 and 8 hours  
 (0.5-hour and 3-hour infusions); 1,000 mg every  
 8 hours (0.5 hour and 3 hour infusions) 
• meropenem 500 mg every 6 hours (0.5-hour  
 infusions); 500 mg, 1,000 mg, and 2,000 mg every  
 8 hours (0.5-hour and 3-hour infusions) 
Pharmacokinetic models
Steady-state exposures for each carbapenem were de-
termined using pharmacokinetic parameter estimates 
obtained from published population pharmacokinetic 
studies undertaken in infected and/or critically ill adult 
patients.1,2 The methods used to simulate these anti-
biotic exposures in adult patients with conserved renal 
function (i.e. creatinine clearance ≥ 50 mL/min) have 
been previously described.3
Monte Carlo simulation
A 5,000 patient Monte Carlo simulation (Crystal Ball 2000; 
Decisioneering Inc., Denver, CO) was performed for each 
regimen, and the probability of a simulated patient achieving 
the pharmacodynamic target, referred to as probability of tar-
get attainment (PTA), was calculated over a range of doubling 
MICs between 0.06 and 64 μg/mL. Pharmacodynamic tar-
gets were defined as free drug concentrations above the MIC 
(fT > MIC) for at least 40% of the dosing interval.4
PTAs for each regimen were used to calculate the cu-
mulative fraction of response (CFR) for each antibiotic 
regimen against the bacteria population. The CFR was cal-
culated as the summation of PTAi*Fi, with the subscript i 
indicating the MIC category ranked from lowest to highest 
MIC value of a population of microorganisms, PTAi being 
the PTA of each MIC category for that drug regimen, and 
F, the fraction of the population of microorganisms at each 
MIC category. A CFR of at least 90% was applied for defin-
ing a regimen as optimal against a bacterial population.
Microbiology
In the present study, the 81 E. coli, 163 K. pneumoniae, 124 
P. aeruginosa, and 34 A. baumannii isolates were obtained from 
the COMPACT-COLOMBIA surveillance program coordinat-
ed in Cali, Colombia by CIDEIM. These isolates were collected 
at CIDEIM between February and November 2009 from 12 
hospitals in Colombia. Characteristics and counts of these iso-
lates are provided in Table 1. Antimicrobial susceptibility test-
ing was conducted by broth microdilution method according to 
the CLSI guidelines using Sensititre plates produced by TREK 
Diagnostic Systems, Inc. (Westlake, OH, USA). The susceptibility 
of doripenem, imipenem, and meropenem against Enterobacte-
riaceae was classified according to the most up-to-date Clinical 
Laboratory Standards Institute (CLSI) published inter-
pretive criteria (MIC ≤ 1 µg/mL).5 For P. aeruginosa and 
Table 1. Numbers of isolates collected during  
COMPACT-COLOMBIA
Isolate E. coli KPN PSA AB
Total No. 81 163 124 34
ICU isolate No. 28 86 81 26
No. by source: 
Bloodstream 33 92 54 18 
cIAI 43 29 27 5 
NP 4 42 43 11
KPN, K. pneumoniae; PSA, P. aeruginosa; AB, A. baumannii; 
No., number; ICU, intensive care unit; cIAI, complicated  
intra-abdominal infection; NP, nosocomial pneumonia isolate.
Pharmacodinamic profile of antibiotics against bacteria in Colombia
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A. baumannii, the susceptibility of imipenem and mero-
penem was classified according to CLSI published interpre-
tive criteria (MIC ≤ 4 µg/mL), whereas U.S. Food and Drug 
Administration (FDA) susceptibility breakpoints were applied 
for doripenem [P. aeruginosa (MIC ≤ 2 µg/mL); A. baumannii 
(MIC ≤ 1 µg/mL)] as no CLSI criteria are currently available 
for this compound.5,6 The MIC50, MIC90 and percent suscep-
tibility for the three carbapenems are presented in Table 2. 
Detailed MIC distributions for each carbapenem against 
P. aeruginosa ICU versus non-ICU isolates are provided 
in Figures 1 and 2 as this was the only organism with 
significant spread of carbapenem MICs to value a visual 
comparison.
Figure 1: Carbapenem MIC distributions against 
P. aeruginosa collected from the ICU. Detailed MIC 
distributions for each carbapenem against P. aeruginosa 
isolates. This was the only organism with significant 
spread of carbapenem MICs to value a visual comparison.
Figure 2: Carbapenem MIC distributions against 
P. aeruginosa collected from outside the ICU. Detailed 
MIC distributions for each carbapenem against 
P. aeruginosa isolates. This was the only organism with 
significant spread of carbapenem MICs to value a visual 
comparison.
Villegas, Briceno, Ruiz et al.
Table 2. MIC50, MIC90, and antimicrobial suscepti-
bility for doripenem, imipenem, and meropenem 
against E. coli, K. pneumoniae, P. aeruginosa, and  
A. baumannii collected from COMPACT-COLOMBIA
Organism (No.) 
    Antibiotic MIC50 MIC90 Susceptibility (%)
Total isolates
E. coli (81) 
Doripenem	 ≤	0.125	 0.25	 97.5 
Imipenem	 0.25	 1	 90.1 
Meropenem	 ≤	0.06	 0.25	 96.3
K. pneumoniae (163) 
Doripenem	 ≤	0.125	 2	 87.1 
Imipenem	 0.5	 8	 81.0 
Meropenem	 ≤	0.06	 4	 86.5
P. aeruginosa (124) 
Doripenem	 0.5	 16	 71.0 
Imipenem 2 64 68.6 
Meropenem 1 32 72.6
A. baumannii (34) 
Doripenem > 16 > 16 44.1 
Imipenem > 8 > 8 44.1 
Meropenem > 8 > 8 44.1
ICU isolates
E. coli (28)  
Doripenem	 ≤	0.125	 0.5	 96.4 
Imipenem	 0.25	 2	 89.3 
Meropenem	 ≤	0.06	 1	 92.9	
K. pneumoniae (86) 
Doripenem	 ≤	0.125	 0.5	 94.2 
Imipenem	 0.5	 2	 86.1 
Meropenem	 ≤	0.06	 0.5	 93.0
P. aeruginosa (81) 
Doripenem	 0.5	 16	 67.9 
Imipenem 4 64 66.7 
Meropenem	 1	 32	 70.4
A. baumannii (26) 
Doripenem	 >	16	 >	16	 30.7 
Imipenem	 >	8	 >	8	 30.7 
Meropenem	 >	8	 >	8	 30.7
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RESULTS
The summary of CFR for all carbapenem regimens against 
the total isolate populations are presented in Table 3. All 
carbapenem regimens obtained optimal exposures against 
E. coli. For the K. pneumoniae isolates, all doripenem and 
meropenem regimens except regimens of doripenem 
500 mg q8h (1-hour infusion) and meropenem 500 mg 
q8h (0.5-hour infusion) exceeded the CFR target value of 
90%. In contrast, the only imipenem regimens to achieve 
this target were the prolonged infusion regimens of 500 mg 
q6h or 1,000 mg q8h. Against P. aeruginosa, imipenem or 
meropenem did not achieved 90% CFR with any regimen. 
While a doripenem regimen of 1,000 mg q8h (over 4h) 
approached (87%) the target CFR, only a prolonged infusion 
of 2000 mg q8h (over 4h) exceeded the 90% CFR threshold. 
Due to very high MICs, no regimens for any of the drugs 
tested obtained optimal CFR against A. baumannii. CFR 
results for ICU versus non-ICU isolates are presented in 
Table 4 for P. aeruginosa and K. pneumoniae. There were 
no differences in CFR between ICU and non-ICU isolates 
for any of the carbapenem regimens against E. coli; there 
were too few isolates outside of the ICU for A. baumannii 
to perform the analyses.
Among P. aeruginosa isolates collected in the ICU 
compared with outside the ICU, there were slight differ-
ences (approximately 5-10%) in CFR among all the drug 
regimens in favor of non-ICU isolates. Again, only dorip-
enem 2,000 mg q8h prolonged infusion regimens achieved 
optimal CFR for both populations. In contrast, CFR for 
K. pneumoniae were greater inside the ICU versus outside 
the ICU by approximately 10-15% depending on dosing 
regimen simulated. 
For these K. pneumoniae, all doripenem and mero-
penem regimens performed well inside the ICU; however, 
outside the ICU, only higher doses of doripenem or pro-
longed infusions, as well as meropenem 2,000 mg q8h 
(3-hour infusion) achieved optimal CFR. Those differences 
may be explained by the fact that in the ICU non- 
susceptibility rates to carbapenems (MIC ≥ 2 μg/mL) 
Table 3. Comparison of the cumulative fraction of response for standard carbapenem regimens against E. coli, 
K. pneumoniae, P. aeruginosa, and A. baumannii
Antibiotic regimen 
                    Cumulative fraction of response (%)
  
(infusion duration) 
  E. coli K. pneumoniae P. aeruginosa A. baumannii
Doripenem 
500	mg	q8h	(1	hr)	 95.9	 88.9	 70.2	 42.2 
1,000	mg	q8h	(1	hr)	 97.8	 92.2	 78.5	 48.9 
2,000	mg	q8h	(1	hr)	 98.7	 94.9	 85.4	 64.6 
500	mg	q8h	(4	hr)	 99.9	 94.0	 79.5	 44.7 
1,000	mg	q8h	(4	hr)	 100	 95.8	 87.2	 53.0 
2,000	mg	q8h	(4	hr)	 100	 97.9	 93.3	 75.0
Imipenem 
500	mg	q8h	(0.5	hr)	 89.9	 79.0	 46.5	 40.4 
500	mg	q6h	(0.5	hr)	 95.4	 85.3	 57.4	 42.5 
1,000	mg	q8h	(0.5	hr)	 93.9	 84.6	 58.5	 41.7 
500	mg	q8h	(3	hr)	 99.5	 89.4	 65.4	 44.1 
500	mg	q6h	(3	hr)	 99.9	 91.1	 69.5	 44.1 
1,000	mg	q8h	(3	hr)	 100	 92.5	 71.8	 44.2
Meropenem 
500	mg	q8h	(0.5	hr)	 98.5	 89.1	 66.1	 42.4 
500	mg	q6h	(0.5	hr)	 99.2	 90.8	 70.0	 43.4 
1,000	mg	q8h	(0.5	hr)	 99.4	 91.7	 72.2	 43.8 
2,000	mg	q8h	(0.5	hr)	 99.7	 93.4	 77.8	 48.7 
500	mg	q8h	(3	hr)	 99.8	 91.7	 72.7	 44.2 
1,000	mg	q8h	(3	hr)	 100	 93.5	 77.6	 45.7 
2,000	mg	q8h	(3	hr)	 100	 95.1	 83.0	 56.4
Pharmacodinamic profile of antibiotics against bacteria in Colombia
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were lower than in the non-ICU setting (5,8% vs. 20,8% 
for doripenem [p = 0.02]; 7% vs. 20.8% for meropenem 
[p = 0.04]; and 14% vs. 24.7% for imipenem [p = 0.13]). 
Differences in resistance rates were more notorious among 
isolates from patients with intra-abdominal infection but 
non-statistically significant differences were obtained due 
to the small sample size (0% vs. 39.1% for doripenem, 
meropenem and imipenem [p = 0.30]). This is the first 
time that such disparities in susceptibility rates have been 
reported in Colombia deserving further studies. 
CFRs were also calculated against all pathogens when 
separated by source of infection: bloodstream, intra- 
abdominal, and nosocomial pneumonia (data not 
shown). Isolates numbers were too small to provide dis-
tinctions among source for A. baumannii and E. coli. For 
P. aeruginosa, CFR was approximately 20% lower for iso-
lates collected in the respiratory tract compared with 
bloodstream or intra-abdominal for imipenem and mero-
penem. Although a similar observation was noted for 
doripenem, the magnitude of the differences were lower 
(approximately 10%), and only doripenem 2,000 mg q8h 
(4-hour infusion) again achieved greater than 90% CFR 
against respiratory P. aeruginosa. For K. pneumoniae iso-
lates, CFR results were highest against bloodstream and 
respiratory tract isolates for all antibiotics. In fact, all 
doripenem and meropenem regimens achieved greater 
than 90% CFR against bloodstream and respiratory isolates 
of K. pneumoniae. CFR against the 29 intra-abdominal 
isolates, however, were 10-20% lower for all antibiot-
ics, suggesting the majority of the resistant phenotype is 
coming from this source.
DISCUSSION
The results of these pharmacodynamic analyses are support-
ed by the high resistance rates among this Colombia col-
lection of P. aeruginosa and A. baumannii, and likewise the 
very low resistance rates of the Enterobacteriaceae. While 
the carbapenems appear to retain very good potency against 
Table 4. Comparison of the cumulative fraction of response for standard carbapenem regimens against  
P. aeruginosa and K. pneumoniae collected from the ICU compared with those collected outside the ICU
Antibiotic regimen 
  Cumulative fraction of response (%)
 
(infusion duration)
   P. aeruginosa   K. pneumoniae 
 ICU (n = 81)  Non-ICU (n = 43) ICU (n = 86)  Non-ICU (n = 77)
Doripenem 
500	mg	q8h	(1	hr)	 69.2	 	 72.1	 92.7	 	 84.7 
1,000	mg	q8h	(1	hr)	 77.6	 	 80.2	 95.2	 	 88.8 
2,000	mg	q8h	(1	hr)	 84.6	 	 86.9	 96.9	 	 92.6 
500	mg	q8h	(4	hr)	 79.2	 	 80.1	 97.3	 	 90.4 
1,000	mg	q8h	(4	hr)	 86.9	 	 87.7	 97.9	 	 93.5 
2,000	mg	q8h	(4	hr)	 92.9	 	 94.1	 98.9	 	 96.8
Imipenem  
500	mg	q8h	(0.5	hr)	 43.0	 	 53.0	 84.4	 	 72.8 
500	mg	q6h	(0.5	hr)	 54.6	 	 62.7	 90.7	 	 79.2 
1,000	mg	q8h	(0.5	hr)	 56.2	 	 62.8	 89.6	 	 79.0 
500	mg	q8h	(3	hr)	 62.7	 	 70.3	 95.1	 	 83.0 
500	mg	q6h	(3	hr)	 67.7	 	 72.9	 96.3	 	 85.3 
1,000	mg	q8h	(3	hr)	 70.2	 	 74.7	 97.2	 	 87.3
Meropenem 
500	mg	q8h	(0.5	hr)	 63.4	 	 71.1	 95.5	 	 82.1 
500	mg	q6h	(0.5	hr)	 63.4	 	 71.1	 95.5	 	 82.1 
1,000	mg	q8h	(0.5	hr)	 70.3	 	 75.7	 97.4	 	 85.2 
2,000	mg	q8h	(0.5	hr)	 76.5	 	 80.3	 98.3	 	 88.0 
500	mg	q8h	(3	hr)	 70.5	 	 77.0	 97.8	 	 84.9 
1,000	mg	q8h	(3	hr)	 76.4	 	 79.8	 98.7	 	 87.7 
2,000	mg	q8h	(3	hr)	 81.9	 	 85.0	 99.1	 	 90.7
Villegas, Briceno, Ruiz et al.
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this population of Enterobacteriaceae, a concerning pheno-
type is the K. pneumoniae with higher carbapenem MICs 
that were most apparent from intra-abdominal cultures ob-
tained outside of the ICU. Therefore for empiric treatment of 
K. pneumoniae in this setting, carbapenem dosages above 
that currently approved may be required. This finding de-
serves further studies as KPC carbapenemases have been 
reported previously and might very well be the cause of 
this resistance.7 Standard (approved) dosing regimens 
of doripenem (500 mg q8h as a 1-hour infusion), meropenem 
(500 mg or 1,000 mg q8h as 0.5-hour infusion and 500 mg q6h 
as a 0.5-hour infusion), and imipenem (500 mg or 1,000 mg 
q8h as 0.5 hour infusion) all achieved optimal CFR against 
E. coli isolates, regardless of collection in or outside of the ICU.
Against A. baumannii, none of the carbapenems achieved 
optimal CFR. More importantly, the very high MICs for iso-
lates in this region also compromise the ability for higher 
doses combined with prolonged infusions to significantly 
improve CFR. The highest CFR against this population of 
34 A. baumannii was obtained by doripenem 2,000 mg q8h 
as a 4-hour infusion (75.0%). Combination therapy or se-
lection of other antimicrobials with unique mechanisms of 
action appears to be required to addressing this high level 
of A. baumannii resistance among ICU isolates. Characteri-
zation of the mechanism of resistance of these isolates de-
serves further studies as OXA-23 carbapenemases have also 
been reported by our group previously and may explain the 
high level resistance to carbapenems.8 The majority of iso-
lates collected during COMPACT-COLOMBIA were from 
the ICU, so conclusions about treatment of A. baumannii 
outside of the ICU cannot be made.
Notably, CFR gains by using higher doses and pro-
longed infusions were observed most frequently against 
the P. aeruginosa population. Standard (approved) doses 
for doripenem and meropenem achieved CFRs of 70.2% 
to 72.2%, while imipenem CFRs were lower than 60%. The 
use of higher doses combined with prolonged infusions 
(unapproved dosing regimens) improved CFR to 93.3% for 
doripenem 2,000 mg q8h (4-hour infusion) and up to 83% 
for meropenem 2,000 mg q8h (3-hour infusion). Although 
prolonged infusions improved CFR for imipenem, the 
inability to administer doses higher than 1,000 mg hin-
dered significant improvements against P. aeruginosa. Even 
1,000 mg q8h (3-hour infusion) only achieved 71.8% 
CFR. The differences between ICU and non-ICU isolates 
were noted among P. aeruginosa as well. As is apparent in 
Figures 1 and 2, the MIC distribution curve is shifted to 
the right for the ICU isolates, thus leading to CFR results 
that are on average 5% to 10% lower for all carbapenems 
compared with isolates outside the ICU. These data sug-
gest that higher dosing, prolonged infusion doripenem 
or meropenem regimens may be suitable for empirically 
covering ICU P. aeruginosa.
Although the in vitro assessment of potency can be an 
important determinant of clinical outcome, the PD profil-
ing undertaken in this study provides additional insight as 
to the clinical viability of these carbapenems by altering the 
dose, dosing interval and/or administration technique to 
overcome phenotypic variations in an adult population 
with conserved renal function as defined herein. It should 
be remembered that additional dosage alterations may be 
required in adult patients with substantially reduced renal 
function and that the simulations provided are not intended 
to be used for special populations (i.e., pediatric patients) 
excluded from the current analysis. Moreover, it is neces-
sary to emphasize that this article utilizes Monte Carlo 
simulation as a predictive tool for clinical success; in clinical 
practice other factors such as host competence and use of 
combination therapies may generate differing outcomes.
Lastly, while the breakpoints for many antibiotics, in-
cluding the carbapenems, are being reduced in an attempt 
to provide more concordance with clinical success, this will 
result in a higher proportion of non-susceptible organisms 
and inadvertent drive clinicians away from pharmacody-
namically sound regimens. Thus, a full understanding of the 
PD characteristics of these therapeutic entities is paramount 
if clinical success is to be maintained in the wake of pheno-
typic change.
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